Skip to content
Open access

IMMF: An Interpretable Multi-Modal Framework for Hypothesis-Driven Biomarker Discovery in Triple-Negative Breast Cancer Using Public Data

Aug 2026 · bioRxiv · 0 citations · 43 references
Biology

TL;DR

An interpretable, multi-modal framework that integrates histopathological image analysis with multi-omics profiling, leveraging U-Net-based nuclei segmentation, vision-language models (BLIP), biomedical language models (BioGPT), and explainable AI is proposed.

Abstract

Triple-Negative Breast Cancer (TNBC) is characterized by high heterogeneity, poor prognosis, and limited targeted treatment options. Bridging the gap between molecular alterations and histopathological morphology remains a major challenge in precision oncology. We propose an interpretable, multi-modal framework that integrates histopathological image analysis with multi-omics profiling (somatic mutations, DNA methylation, copy number alterations), leveraging U-Net-based nuclei segmentation, vision-language models (BLIP), biomedical language models (BioGPT), and explainable AI (SHAP, LIME). Our framework achieves strong predictive performance (AUC = 0.989) and provides transparent, biologically grounded interpretations by integrating morphological features with genomically prioritized biomarkers. Cross-modal analysis confirms established TNBC drivers and generates novel, testable hypotheses associating specific epigenetic alterations with distinct morphological phenotypes. While causal validation requires future wet-lab experiments, our framework accelerates hypothesis-driven biomarker discovery by integrating complementary data modalities with language-based reasoning, providing a transparent foundation for hypothesis generation and clinical translation.

Read PDF

Similar papers

Review Open access Sep 2026

AI-driven multi-omics biomarkers in precision breast cancer therapeutics: from discovery to clinical translation

Breast cancer is biologically heterogeneous, yet conventional clinical decisions rely on static, single-marker proxies (ER, PR, HER2, and Ki-67) that capture only a narrow slice of tumor biology. This mini-review argues that AI-driven multi-omics biomarkers offer a valuable shift toward systems-level, model-derived pro...

D. Stylianakis, R. Sánchez-Bayona, N. Denaro et al. · 0 citations
Open access Aug 2026

Explainable Multi-Omics Transformer Risk Stratification in Lung Adenocarcinoma: External Validation, Calibration, and Patient-Level Genomic Attribution

- Lung adenocarcinoma (LUAD) remains biologically heterogeneous and clinically difficult to stratify with a single data modality. Transformer architectures can, in principle, model cross-modality interactions among RNA expression, somatic mutation, copy-number variation (CNV), and clinical variables, but their clinical...

Cleopas Russell Choga, Manyara Sandra Kasanhayi, Nkosana Mkandla et al. · 0 citations
Open access Sep 2026

AI‑Driven Multi‑Omics Integrative Model for Predicting Tumor‑Specific Drug Responses

Precision oncology requires robust drug-response prediction because single biomarkers cannot fully explain therapeutic variation across tumors, cell lines, and drug structures. This study develops an AI-driven multi-omics model using GDSC, CCLE, DepMap, CTRP, and TCGA data, integrating mutation, copy-number variation,...

Xin-Yuan Kang, Ai-Lin Deng · 0 citations
Open access Aug 2026

Identifying multi-omics biomarkers for ovarian cancer survival estimation

An interpretable three-stage machine learning framework integrating mRNA, microRNA, DNA methylation, copy number variation, and protein expression data from The Cancer Genome Atlas that couples improved prognostic estimation with biological interpretability supporting multi-omics biomarker discovery in ovarian cancer.

Kosar Fateh, S. Sathipati · 0 citations
Open access Sep 2026

Deep learning-based large-scale pan-cancer multiple biomarkers prediction using RIDGE with pathological images

Molecular profiling tests currently relies significantly on genomics or transcriptomics analysis, leading a prolonged turnaround time and higher costs procedure. This comprehensive pan-cancer study aims to develop a general, weakly supervised, and clinically interpretable deep learning (DL) approach for predictin...

Hao-Ran Xi, Xiao-Bing Feng, Ye Lu et al. · 0 citations
Review Open access Sep 2026

The next-generation biomarkers in early-stage triple negative breast cancer.

Multibiomarker integration, supported by prospective validation and automated models, represents a promising approach to personalize treatment algorithms in early-stage TNBC, balancing efficacy and toxicity while guiding escalation and de-escalation strategies.

Federica Falcone, Erica Pietroluongo, P. De Placido · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.